We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Antisoma | ASM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.325 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.325 | 1.325 |
| Top Posts |
|---|
Posted at 31/10/2013 09:40 by minho What a sorry state of affairs. 2006 -2007 went from 12 p to 60p on possible good medical results. Antisoma tried real hard to crack the cancer blight, real pity it failed. At least they really had a good go at it. OXB 5p to 50p same,wife of ceo sold her total holding at 54p after that I never went back in. There is a huge failure list but I did believe in the possible good outcome of quite a few of these research stocks, as like so many of us we have lost loved ones to this terrible disease We live in hope. ASM might just develop a game changer yet. |
Posted at 11/7/2012 19:57 by jsbach123 There are convincing arguments that when a company clearly has failed but still has some assets to wind it up and return whatever value there is left to shareholders. Or if that is too complex and majority shraeholders are desperate to keep it trading perhaps ASM should reinvent itself as a tracker fund - more profitable probably johnsmith than the 'range of smaller investments' you envisage. |
Posted at 26/10/2011 13:58 by fillipe My guess is that the move to the AIM will coincide with a merger or suchlike with one of ORA's other investments.I've had ASM in the past and done ok with them....have just taken 75k shrs which doesn't show up on either Level 2 or Plus, on the strength of eventually something worthwhile coming up as a result of the ORA holding. gla f |
Posted at 15/6/2011 12:53 by jsbach123 I'd still be happy to get my share of whatever little is left even at 0.75p as suggested by gdasinv2 and see ASM closed. You win some...you lose some. |
Posted at 20/5/2011 09:44 by cumnor Feel the company has done well in managing wind-down, bearing in mind the sensitivities of staff who have worked for years for asm. Remember this company up to three months ago had many well paid well qualified full time scientists/managers etc working so of course it is appropriate that all RNSs stick to the point re current proceedings without emphasing the point that the company has cash, new investors and a strategy in place to reward shareholders while at the same time giving out P60s. Now they have done the necessary i suspect the next RNs's will be focused more clearly on strategy to interest shareholders with probable news on mergers/ acquisitions or even buyout. Ora I suspect already know exactly what is going to happen. imo |
Posted at 20/5/2011 09:04 by cumnor 6 weeks. Still has ip and opportunities, particularly small mining/oil companies, have been devestated over the past three months giving ASM the chance to acquire assets much cheaper than before, even when they had more cash. This is what recovery plays are all about and positioning yourself for the next move. This is where the value of a listing comes into play and with a few heavyweight investors on board not just sitting to take pensions and with shareholders to ansewr to there should be some action soon. But clearly it would be nice to see them moving soon and the listing will facilitate this imo. Considering the size of the company cash burn way less than expected imo. |
Posted at 03/5/2011 12:04 by cumnor I think in two or three years we will see a very different ASM with a totally new business and share price multiples of what it is now, still a plc. The fact they did'nt just go for an all cash deal for some of the ip, retaining possibility of royalties and the interest which will have real resale value as and when the product is progressed, suggests to me they have a definite goal and we should start to see newsflow soon as the formalities of winding down the old ASM and reinvesting remaining cash unfold. imo dyor |
Posted at 28/4/2011 08:10 by cumnor Good news I feel. Suggests intention to remain listed but with completely different focus, possibly having taken on some private co like o/g or minerals explo and with significant cash reserves and backing of respected aggresive equity partners this could be due rerating thereafter. Also possibility of decent royalty returns (that is all it could ever have expected and not much less than normL) on it's total antibody ip which will cost nothing and be developed by larger pharma with clout to get anything out of it if it is going to succeed. I am happy to see it with smaller sale price but potential for decent returns long term if it's drugs turn up trumps as keeps investors interested and adds value at each stage if it passes trials. All speculation but i don't think ORA will be happy with anything less than 30p exit at some stage. Cash reserves important but backing of respected large investors and listing could take this anywhere. Certainly things happening as we hoped. Could we see renewed asm with much higher share price in a year or two. I think so. aimo dyor |
Posted at 09/3/2011 15:59 by freddie ferret I said that the management of ASM were decisive, todays RNS shows how they are cutting costs, having already dispensed with most of the board. Interesting to see what they have planned, watch this space.9 March 2011, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that it has undertaken a substantial reduction in staff numbers in accordance with the announcement on 8 February that the Company would take steps to conserve its cash resources. Total headcount has now been reduced to around 10 staff and will fall further next month. The following members of the Senior Management Team have left or will shortly be leaving the Company: Gary Acton (Chief Medical Officer), Nicholas Adams (VP, Business Development), Michael Boss (General Manager, Autoimmune), Daniel Elger (VP, Marketing and Communications), Sharon Grimster (VP, Regulatory, Pharmaceutical and Business Operations) and Chris Smyth (VP, Clinical Operations). |
Posted at 11/2/2011 09:01 by pwhite73 Because companies always trade at multiples of a premium to their cash level. In the case of ASM they have an amount of cash that others can only dream of.Sareum are capitalised £27 million. They raised £500K on the back of frenetic buying. Its the only cash they have plus an unprovable compound tested on a rat for goodness sake. ASM are capitalised at £15 million and have £23 million in the bank. The directors of SAR would gladly swap places with the directors of ASM any day. Anyway enough said for now and just watch the shareprice take care of itself. Cash is king. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
